The present invention relates to the treatment of cancer. Here, the inventors evaluated EAPB02303 effects in PDAC cell lines and mouse models and […]

Immunotherapy has transformed cancer treatment but often struggles with solid tumors due to immune resistance from the tumor microenvironment (TME). […]

The present invention relates to the treatment of brain or neurologic disorders. In this study, the inventors hypothesized that a Fc receptor (FcRn) […]

Melanoma cell plasticity plays a key role in the acquisition of resistance to therapy. TRIM24/TIF1α, which encodes for the tripartite […]

The Inventors herein demonstrate that CD39 is a relevant therapeutic target in B-celllymphoma, in particular Follicular Lymphoma (FL), Diffuse Large […]

Thanks to its very high genome-editing efficiency, CRISPR-Cas9 technology could be a promising anti-cancer weapon. Clinical trials using CRISPR-Cas9 […]

PTLDs arise after solid organ and hematopoietic stem cell transplants, with occurrences linked to immunosuppressive therapy and EBV status. Initial […]

The role of pro- and anti-inflammatory macrophages in disease depends on the specific disease and the balance between the two types of macrophages. […]

Circulating tumor DNA (ctDNA) is a promising non-invasive biomarker in cancer. The inventors aim to assess the dynamic evolution of ctDNA in patients […]

Inventors demonstrated that an epigenetic regulator CBX3 antagonizes IFNγ signalling via directly repressing the transcription of two key […]